1-4 of 4
Daniel J. Hicklin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A074: Discovery of WTX-330, a clinical stage conditionally activated IL-12 INDUKINETM therapeutic with potent antitumor activity in murine syngeneic tumor models resistant to checkpoint blockade

Christopher J Nirschl, Heather R Brodkin, Sameer S Chopra, Connor J Dwyer, Daniel J Hicklin, Randi Isaacs, Nesreen Ismail, Cynthia Seidel-Dugan, Zoe Steuert, Jenna M Sullivan, William M Winston, Andres Salmeron
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A074.
https://doi.org/10.1158/1535-7163.TARG-23-A074
Published: 01 December 2023
View articletitled, Abstract A074: Discovery of WTX-330, a clinical stage conditionally activated IL-12 INDUKINETM therapeutic with potent antitumor activity in murine syngeneic tumor models resistant to checkpoint blockade
Journal Articles

SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

Andrea D. Basso, Ming Liu, Chaoyang Dai, Kimberly Gray, Lissette Nale, Seema Tevar, Suining Lee, Lianzhu Liang, Abdul Ponery, Bohdan Yaremko, Elizabeth Smith, Huadong Tang, Payal R. Sheth, M. Arshad Siddiqui, Daniel J. Hicklin, Paul Kirschmeier
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (11): 2993–3002.
https://doi.org/10.1158/1535-7163.MCT-10-0548
Published: 09 November 2010
View articletitled, SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics
Open the PDF for SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics in another window
Includes: Supplementary data
Journal Articles

Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target

Nick Loizos, Yan Xu, Jim Huber, Meilin Liu, Dan Lu, Bridget Finnerty, Robin Rolser, Asra Malikzay, Anita Persaud, Erik Corcoran, Dhanvanthri S. Deevi, Paul Balderes, Rajiv Bassi, Xenia Jimenez, Christopher J. Joynes, Venkata R.M. Mangalampalli, Philipp Steiner, James R. Tonra, Yan Wu, Daniel S. Pereira, Zhenping Zhu, Dale L. Ludwig, Daniel J. Hicklin, Peter Bohlen, Larry Witte, Paul Kussie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (3): 369–379.
https://doi.org/10.1158/1535-7163.MCT-04-0114
Published: 14 March 2005
View articletitled, Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target
Open the PDF for Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target in another window
Journal Articles

Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti–vascular endothelial growth factor receptor-2 antibody

Alexander L. Rakhmilevich, Andrea T. Hooper, Daniel J. Hicklin, Paul M. Sondel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (8): 969–976.
https://doi.org/10.1158/1535-7163.969.3.8
Published: 06 August 2004
View articletitled, Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti–vascular endothelial growth factor receptor-2 antibody
Open the PDF for Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti–vascular endothelial growth factor receptor-2 antibody in another window